Health Economics›Multiple myeloma›First-line therapy other

First-line therapy other

Multiple myeloma · 10 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Total Therapy N/A - protocol	—	R 39 668	28d	—	—	~27	~R 804 533 indirect	—
TVAD (Pegylated liposomal doxorubicin substituted) Variant #01	—	R 34 234	28d	—	—	~4	~R 134 160 indirect	—
VMP, then Rd Variant #01	—	R 26 292	42d	—	—	~9	~R 120 713 indirect	—
VMP/Rd Variant #01	—	R 26 292	42d	—	—	~9	~R 120 713 indirect	—
VAD (Pegylated liposomal doxorubicin substituted) Variant #01	—	R 17 552	28d	—	—	~4	~R 67 431 indirect	—
VTD-PACE Variant #01	—	R 11 753	—	—	—	~2	~R 23 506 indirect	—
VAD-P/Q Variant #01	—	R 7 937	21d	—	—	~10	~R 79 371 indirect	—
CVAD Variant #01	—	R 2 008	21d	—	—	~7	~R 14 058 indirect	—
VAD-P Variant #01	—	R 1 463	21d	—	—	~10	~R 14 630 indirect	—
Zoledronic acid therapy Variant #01	—	—	28d	—	50.0 mo	—	—	1

10 of 10 regimens shown